Delta buys 49% stake in Virgin Atlantic

Delta Air Lines said it will buy almost half of Virgin Atlantic for $360 million as it tries to catch up to rivals in the lucrative New York-to-London travel market.

Delta plans to form a joint venture with Virgin Atlantic so they can sell seats on each other's flights, share the costs and profits, and set the flight schedules in ways that help both airlines. American Airlines has a similar deal with British Airways.

Because Delta would be setting fares and schedules in coordination with an airline it used to compete with, it said it will need antitrust approval from U.S. and European regulators in order to form a joint venture. Delta said the share purchase will happen with or without antitrust approval.

Delta is aiming to have the joint operation running by the end of 2013.

The deal won't add flights between the U.S. and Britain. But travel will be more seamless. Travelers would be able to buy one plane ticket from, say, Lansing, Michigan on Delta and connect in New York to a Virgin Atlantic flight to London. Travelers from Europe will also have a smoother transition onto Delta flights to locations inside the U.S. Delta said their frequent flier programs would be linked, too.

Combined, Delta and Virgin Atlantic have 31 flights a day in each direction between North America and the U.K., including nine each way between Heathrow and John F. Kennedy International Airport in New York and Newark Liberty International Airport in New Jersey.

By itself, Delta has only three flights a day straight from New York to Heathrow. American and British Airways have 14 between them. And that's the problem. New York-to-London and back is one of the world's prime business travel routes. Delta has loads of travelers coming into its New York hubs at JFK and LaGuardia. But without more flights to bring those travelers on to London, Delta is at a serious disadvantage.

Landing rights at London's Heathrow Airport are limited, so Delta can't just add more flights there.

Buckingham Research analyst Daniel McKenzie wrote that Delta needed to fix its shortfall of London flights in order to win more business travelers. He estimated that the deal would bring Delta hundreds of millions of dollars in added revenue starting in 2014. Some of that business will probably come at American's expense, since it also has a hub at JFK, McKenzie wrote.

Sir Richard Branson will still own more than half of Virgin Atlantic, which will continue to fly as a separate airline under its own name. In 2000, Branson sold a stake to Singapore Airlines for 600.3 million pounds, or about $960 million at the time. That's the share that Delta is buying.

Virgin Atlantic has been struggling. It reported a pretax operating loss of 80.2 million British pounds in its most recent fiscal year, even as the number of passengers it carried rose 2 percent. It indicated in 2010 that it might be interested in some kind of tie-up with another airline. British media reports at that time said that Delta was interested.

Branson's involvement gives Virgin Atlantic strong name recognition, but it is much smaller than Delta. Virgin Atlantic has 38 planes, compared to 725 for Delta. Delta carries some 160 million passengers per year, almost 30 times more than Virgin Atlantic.

Shares of Atlanta-based Delta Air Lines Inc. rose 60 cents, or 5.9 percent, to $10.74 in morning trading.




India revokes patent on Merck & Co's asthma drug

w Delhi, Dec 11 (PTI) Indian Patents Office has revoked a patent for an asthma drug held by US-based Merck & Co following a challenge from domestic pharma firm Cipla.

In an order, Assistant Controller of Patents & Designs T V Madhusudhan revoked the patent on the ground that it lacked invention.

"The sole process claim also in its entirety is not inventive as the said claim does not describe any inventive feature," the order said.

"In view of the above conclusion I hereby order that the patent bearing number 246328 is revoked," Madhusudhan said in his order.

Schering Corporation, which was later acquired by Merck & Co, had applied for patent of the asthma drug in February 2004, and the Indian Patents Office had granted the patent in March 2011. Cipla had challenged the patent.

The development is the latest in a series of patent revocations by India's Patent Office.

Last month, the Intellectual Property Appellate Board (IPAB) had turned down drug firm AstraZeneca's plea for a patent on the lung cancer drug Gefitinib.

Similarly, it had also revoked Pfizer's patent on cancer drug 'Sutent'. The drug was granted a patent in India in 2007 but Cipla had opposed it the following year.

Earlier during the year, India Patents Office had invoked compulsory licensing permitting the Hyderabad-based Natco Pharma to manufacture and sell cancer-treatment drug Nexavar at a price, over 30 times lower than charged by its patent-holder Bayer Corporation.

Air India, Airline, Aviation, Ground handling
likely to raise cap on LPG cylinders: